TT 173

Drug Profile

TT 173

Alternative Names: TT-103; TT-103MH; TT-173; Yeast-derived microvesicles containing recombinant Tissue Factor

Latest Information Update: 24 Dec 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Thrombotargets Corporation
  • Class Antihaemorrhagics; Recombinant proteins
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Von Willebrand disease; Haemophilia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Blood coagulation disorders

Most Recent Events

  • 09 Dec 2015 Phase-II/III clinical trials in Coagulation disorders in Spain (Topical, Powder) (EudraCT2015-003408-21)
  • 04 Oct 2013 Phase-II clinical trials in Coagulation disorders in Spain (Topical)
  • 01 Sep 2013 Thrombotargets completes a phase I trial for Coagulation disorders in Spain (NCT01595360)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top